{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T06:46:50Z","timestamp":1772261210812,"version":"3.50.1"},"reference-count":18,"publisher":"National Center for Global Health and Medicine (JST)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["GHM"],"published-print":{"date-parts":[[2026,2,25]]},"DOI":"10.35772\/ghm.2025.01131","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T22:08:53Z","timestamp":1769206133000},"page":"53-58","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic comparison between osteoblastic and osteolytic metastases in prostate cancer"],"prefix":"10.35772","volume":"8","author":[{"given":"Akihiro","family":"Ono","sequence":"first","affiliation":[{"name":"Department of Urology, NTT Medical Center Tokyo, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Akiyama","sequence":"additional","affiliation":[{"name":"Department of Urology, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryohei","family":"Nishimoto","sequence":"additional","affiliation":[{"name":"Department of Urology, NTT Medical Center Tokyo, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Amakawa","sequence":"additional","affiliation":[{"name":"Department of Urology, NTT Medical Center Tokyo, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Urology, NTT Medical Center Tokyo, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Yoshimatsu","sequence":"additional","affiliation":[{"name":"Department of Urology, NTT Medical Center Tokyo, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Shiga","sequence":"additional","affiliation":[{"name":"Department of Urology, NTT Medical Center Tokyo, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Kusakabe","sequence":"additional","affiliation":[{"name":"Department of Radiology, NTT Medical Center Tokyo, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruyasu","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Radiology, NTT Medical Center Tokyo, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Taguchi","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruki","family":"Kume","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Urology, NTT Medical Center Tokyo, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"21485","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019; 10:63-89.","DOI":"10.14740\/wjon1191"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Chikamatsu S, Shiota M, Onozawa M, Hinotsu S, Kitagawa Y, Sakamoto S, Kawai T, Eto M, Kume H, Akaza H; Japan Study Group of Prostate Cancer (J-CaP). Dynamics of conditional survival and risk factors in androgen deprivation therapy for prostate cancer using a multi-institutional Japan-wide database. Int J Urol. 2021; 28:927-935.","DOI":"10.1111\/iju.14605"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Corsini C, Garmo H, Orrason AW, Gedeborg R, Stattin P, Westerberg M. Survival trend in individuals with de novo metastatic prostate cancer after the introduction of doublet therapy. JAMA Netw Open 2023; 6:e2336604.","DOI":"10.1001\/jamanetworkopen.2023.36604"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Bubendorf L, Sch\u00f6pfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ. Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients. Hum Pathol. 2000; 31:578-583.","DOI":"10.1053\/hp.2000.6698"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Carlin BI, Andriole GL. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 2000; 88:S2989-S2994.","DOI":"10.1002\/1097-0142(20000615)88:12+<2989::AID-CNCR14>3.0.CO;2-Q"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Liu D, Kuai Y, Zhu R, Zhou C, Tao Y, Han W, Chen Q. Prognosis of prostate cancer and bone metastasis pattern of patients: A SEER-based study and a local hospital based study from China. Sci Rep. 2020; 10:9104.","DOI":"10.1038\/s41598-020-64073-6"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Russo S, Scotto di Carlo F, Gianfrancesco F. The osteoclast traces the route to bone tumors and metastases. Front Cell Dev Biol. 2022; 10:886305.","DOI":"10.3389\/fcell.2022.886305"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Kurokawa R, Kato S, Koyama H, Ishida M, Kurokawa M, Kuroda R, Ushiku T, Kume H, Abe O. Osteolytic or mixed bone metastasis is not uncommon in patients with high-risk prostate cancer. Eur J Radiol. 2022; 157:110595.","DOI":"10.1016\/j.ejrad.2022.110595"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Roudier MP, Morrissey C, True LD, Higano CS, Vessella RL, Ott SM. Histopathological assessment of prostate cancer bone osteoblastic metastases. J Urol. 2008; 180:1154-1160.","DOI":"10.1016\/j.juro.2008.04.140"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Wong SK, Mohamad NV, Giaze TR, Chin KY, Mohamed N, Ima-Nirwana S. Prostate cancer and bone metastases: The underlying mechanisms. Int J Mol Sci. 2019; 20:2587.","DOI":"10.3390\/ijms20102587"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. DiNatale A, Worrede A, Iqbal W, Marchioli M, Toth A, Sj\u00f6str\u00f6m M, Zhu X, Corey E, Feng FY, Zhou W, Fatatis A. IL1\u03b2 expression driven by androgen receptor absence or inactivation promotes prostate cancer bone metastasis. Cancer Res Commun. 2022; 2:1545-1557.","DOI":"10.1158\/2767-9764.CRC-22-0262"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Liao R, Feng Z, Li W, Liu R, Xu X, Yao S, Tian J. Interleukin-1 induces receptor activator of nuclear factor-\u03baB ligand-independent osteoclast differentiation in RAW264.7 cells. Exp Ther Med. 2021; 21:640.","DOI":"10.3892\/etm.2021.10072"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Tamura T, Yamamoto T, Kogure A, Yoshioka Y, Yamamoto Y, Sakamoto S, Ichikawa T, Ochiya T. Extracellular vesicles from prostate cancer\u2010corrupted osteoclasts drive a chain reaction of inflammatory osteolysis and tumour progression at the bone metastatic site. J Extracell Vesicles. 2025; 14:e70091.","DOI":"10.1002\/jev2.70091"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Smith MR, Saad F, Coleman R, <i>et al<\/i>. Denosumab and bone metastasis-free survival in men with castration-resistant prostate cancer: Results of a global phase 3, randomised, placebo-controlled trial. Lancet. 2012; 379:39-46.","DOI":"10.1016\/S0140-6736(11)61226-9"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Langsenlehner T, Pichler M, Thurner EM, Krenn-Pilko S, Stojakovic T, Gerger A, Langsenlehner U. Evaluation of the platelet-to-lymphocyte ratio as a prognostic indicator in a European cohort of patients with prostate cancer treated with radiotherapy. Urol Oncol. 2015; 33:201.e9-e16.","DOI":"10.1016\/j.urolonc.2015.02.002"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. O&apos;Sullivan GJ, Carty FL, Cronin CG. Imaging of bone metastasis: An update. World J Radiol. 2015; 7:202-211.","DOI":"10.4329\/wjr.v7.i8.202"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Liu F, Dong J, Shen Y, Yun C, Wang R, Wang G, Tan J, Wang T, Yao Q, Wang B, Li L, Mi J, Zhou D, Xiong F. Comparison of PET\/CT and MRI in the diagnosis of bone metastasis in prostate cancer patients: A network analysis of diagnostic studies. Front Oncol. 2021; 11:736654.","DOI":"10.3389\/fonc.2021.736654"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Herroon MK, Diedrich JD, Rajagurubandara E, Martin C, Maddipati KR, Kim S, Heath EI, Granneman J, Podgorski I. Prostate tumor cell-derived IL-1\u03b2 induces an inflammatory phenotype in bone marrow adipocytes and reduces sensitivity to docetaxel <i>via<\/i> lipolysis-dependent mechanisms. Mol Cancer Res. 2019; 17:2508-2521.","DOI":"10.1158\/1541-7786.MCR-19-0540"}],"container-title":["Global Health &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ghm\/8\/1\/8_2025.01131\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T04:21:01Z","timestamp":1772252461000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ghm\/8\/1\/8_2025.01131\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.35772\/ghm.2025.01131","relation":{},"ISSN":["2434-9186","2434-9194"],"issn-type":[{"value":"2434-9186","type":"print"},{"value":"2434-9194","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"article-number":"2025.01131"}}